

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 19, 2025

CD62L (L-Selectin)

RRID:AB_2744441

Type: Antibody

Proper Citation

(BD Biosciences Cat# 562719, RRID:AB_2744441)

Antibody Information

URL: http://antibodyregistry.org/AB_2744441

Proper Citation: (BD Biosciences Cat# 562719, RRID:AB_2744441)

Target Antigen: CD62L (L-Selectin)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD62L (L-Selectin)

Description: This monoclonal targets CD62L (L-Selectin)

Target Organism: human

Clone ID: DREG-56

Antibody ID: AB_2744441

Vendor: BD Biosciences

Catalog Number: 562719

Alternative Catalog Numbers: 562720

Record Creation Time: 20231110T033441+0000

Record Last Update: 20240725T005620+0000

Ratings and Alerts

No rating or validation information has been found for CD62L (L-Selectin).

No alerts have been found for CD62L (L-Selectin).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. Cell reports, 43(2), 113712.

Klysz DD, et al. (2024) Inosine induces stemness features in CAR-T cells and enhances potency. Cancer cell, 42(2), 266.

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer cell, 42(1), 35.

Pezzella M, et al. (2024) Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. Journal of hematology & oncology, 17(1), 127.

Heitzeneder S, et al. (2022) GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer cell, 40(1), 53.

Yang C, et al. (2022) Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. Immunity, 55(7), 1268.

Labanieh L, et al. (2022) Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell, 185(10), 1745.

Smole A, et al. (2022) Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer cell, 40(12), 1470.

Weulersse M, et al. (2020) Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity, 53(4), 824.

Du H, et al. (2019) Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer cell, 35(2), 221.